Perceptive Advisors Increases Stake in MGTX with Recent Purchase

Perceptive Advisors LLC made a notable move on June 11, 2026, by acquiring 60,000 shares of MGTX. The transaction didn't involve any cash exchange as the shares were priced at $0.00. On the same day, shares of MGTX were trading at approximately $9.75.

What Changed in Perceptive Advisors' MGTX Position

Perceptive Advisors' recent acquisition adds 60,000 shares to its holdings in MGTX. This purchase reflects continued interest in the company, although the transaction details indicate the shares were acquired at no cost.

Other Institutional Activity in MGTX

Other funds have also been active with MGTX. Rubric Capital Management LP increased its holdings by 824,669 shares, bringing its total to 7,000,000 shares valued at around $60.62 million. Millennium Management LLC also added to its position, raising its stake by 289,309 shares to a total of 3,465,699 shares, worth $30.01 million. Meanwhile, Sanofi, Perceptive Advisors LLC, and Adage Capital Partners GP, L.L.C. maintained their positions without changes.

MeiraGTx Holdings plc Stock Down 29.5%

MGTX's stock, trading at $9.75, has drawn attention from various investors. The company's market activity indicates a steady interest, with several funds adjusting their positions. The stock's value and trading volume reflect its ongoing appeal in the market.

Insider Buying and Selling at MeiraGTx Holdings plc

Several insiders have been active recently. Perceptive Advisors LLC purchased 60,000 shares on June 11, 2026. On June 10, 2026, Keith Harris sold 75,000 shares and also bought 75,000 shares. Richard Giroux, CFO & COO, sold 7,000 shares on May 27, 2026, and President & CEO Alexandria Forbes sold 62,000 shares on May 19, 2026, under a planned transaction. Chief Development Officer Penny Renee Fleck bought 100,000 shares on May 13, 2026.

Analysts Set New Price Targets

Analysts have maintained positive outlooks on MGTX. On May 15, 2026, RBC Capital maintained a 'buy' rating with a $25 price target. Piper Sandler also maintained a 'buy' rating with a $30 target on April 22, 2026. Evercore ISI Group and B of A Securities have also expressed confidence with respective targets of $18 and $16.

About MGTX

MGTX focuses on developing innovative treatments in the biotechnology sector. The company is involved in the research and development of gene therapies aimed at addressing unmet medical needs. MGTX is committed to advancing healthcare solutions through cutting-edge technology and scientific expertise.

Bottom Line

Perceptive Advisors' purchase of 60,000 shares of MGTX underscores the continued interest in the company's potential. The activity among institutional investors and analysts' positive ratings suggest MGTX remains an attractive option in the biotech space. As always, remember that insider transactions and analyst ratings are backward-looking indicators and may not reflect the current market conditions.